Start Your Free Portfolio Tracker Today
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
ARIAD/Specialised Therapeutics Join Forces for Iclusig
ARIAD Pharmaceuticals, Inc. ( ARIA - Analyst Report) announced that it has granted exclusive rights to Specialised Therapeutics Australia Pty Ltd. to commercialize Iclusig in Australia. In the third quarter of 2013, ARIAD submitted a marketing application for Iclusig for the treatment of Philadelphia-positive (Ph+) leukemia to the Therapeutic Goods Administration (TGA) in Australia.
Per the terms of the deal, Specialised Therapeutics will be responsible for obtaining marketing authorization and pricing and reimbursement approval of Iclusig in Australia. Furthermore the Australian company will also assist ARIAD in regulatory filings for Iclusig in Australia.
The agreement is for seven years from the first commercial sale of Iclusig in Australia. ARIAD will have the option to take over the commercialization rights or extend the deal with Specialised Therapeutics following the expiry of the seven-year period.
ARIAD expects Iclusig to be approved and launched in Australia in the fourth quarter of 2014. However, prior to the market launch, it will be available under a Special Access Program for patients suffering from chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).
As per data from the Australian Institute of Health and Welfare, currently there are over 1500 patients in Australia being treated for CML. The incidence of the disease is on the rise.
ARIAD has witnessed many ups and downs regarding Iclusig over the last few quarters. Earlier in the month, the company announced that Iclusig was once again available in the U.S. after the marketing and commercial distribution of the drug was temporarily suspended in Oct 2013. The drug was temporarily banned following instructions from the U.S. regulatory authority in the wake of a higher-than-expected incidence of blood clots and narrowing of blood vessels.
ARIAD's shares were battered by the Oct 2013 development. The stock has regained some ground since then. We expect investor focus to remain on Iclusig going forward.
ARIAD carries a Zacks Rank #2 (Buy). Some other stocks worth considering include Actelion Ltd. ( ALIOF - Snapshot Report) , Affymetrix Inc. and Gentium S.p.A . All stocks carry a Zacks Rank #1 (Strong Buy).